December 8, 2024 PAI Top-10 Product Launch

Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line diffuse large B-cell lymphoma (DLBCL)1 Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems1 These... Read more

December 5, 2024 Acad, Gov/Utilities PAI Top-10

FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

Application is based on data from the phase III STARGLO study where Columvi plus chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival1,2 This regimen could provide an off-the-shelf, fixed-duration treatment option for patients to start soon after diagnosis, which is important for those who are at high-risk of disease progression Improving... Read more

December 4, 2024 Lab Top-10

Thermo Fisher Scientific Completes $1B Share Repurchase

WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the repurchase of $1 billion (1.9 million shares) of its common stock. As of December 3, 2024, $3 billion remained available under the company’s share repurchase authorization. About Thermo Fisher Scientific Thermo Fisher Scientific... Read more

December 2, 2024 Lab Top-10 PAI Top-10

Bruker Introduces Dimension Nexus™ Atomic Force Microscope

Upgradable Large-Sample System Sets New Performance Standard for Cost-Effective AFMs SANTA BARBARA, Calif.–(BUSINESS WIRE)– At the 2024 MRS Fall Meeting & Exhibit, Bruker Corporation (Nasdaq: BRKR) today announced the launch of the Dimension Nexus™ atomic force microscope (AFM). Dimension Nexus is the newest addition to the industry-leading Dimension® AFM product line, which has had more... Read more

November 26, 2024 Clinical Research/Diagn. M&A, Partnerships

Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapies Roche to acquire Poseida Therapeutics for US $9.00 per share in cash at closing, representing a total equity value of approximately US... Read more

November 26, 2024 Bio/Pharma/CRO

Roche reports update on Phase III SKYSCRAPER-01 study results

Basel, 26 November 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq® (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC).  SKYSCRAPER-01 is a global phase III, randomised, double-blind study evaluating tiragolumab plus... Read more

November 18, 2024 Lab Top-10

Bruker Announces Quarterly Dividend

BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on December 16, 2024 to stockholders of record as of December 2, 2024. About Bruker Corporation... Read more

November 12, 2024 Lab Top-10

Bruker Corporation to Present at Upcoming Investor Conferences

BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: Stifel 2024 Healthcare Conference in New York City Monday, November 18, 2024, at 8:35 a.m. Eastern Time Wolfe Research 2024 Healthcare Conference in New York City... Read more